Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01684904 · ClinicalTrials.gov registry record · NA
Proton Therapy for Esophageal Cancer
A NA study of Esophagus Cancer, sponsored by Loma Linda University.
- Recruiting
- Registry status
- NA
- Development phase
- 38
- Enrollment target
- 1
- Study location
NCT01684904: Recruiting NA study of Esophagus Cancer, sponsored by Loma Linda University.
NCT01684904 is a NA study of Esophagus Cancer that is actively recruiting participants, run by Loma Linda University. The registered enrollment target is 38 participants, below the 485-participant average among 11 other Esophagus Cancer trials with a reported enrollment target (92% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01684904, a NA study of Esophagus Cancer, is actively recruiting participants, sponsored by Loma Linda University.
- RECRUITING
- Registry status
- NA
- Development phase
- 38 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this phase II study is to investigate the feasibility, toxicity and efficacy of a regimen incorporating a proven systemic regimen, carboplatin /paclitaxel, with conformal proton modality, followed by definitive surgery. In most combined-modality trials to date, chemotherapy regimens have included cisplatin, usually in conjunction with 5-fluorouracil. In designing the regimen, the investigators attempt to improve on the standard cisplatin/5-fluorouracil regimen in several ways. First, full-dose paclitaxel is added to the regimen. This agent has activity against advanced esophageal cancer and is also a potent radiosensitizer. Second, the substitution of carboplatin for cisplatin has resulted in reduced toxicity of various combination regimens similar to that used by CROSS trial and allows for easier administration in the outpatient setting.4 Third, for localized esophageal cancer, dose distribution patterns achievable with proton beam could potentially offer important clinical advantages relative to those achievable with x-rays (photons).19 Based on this, the investigators believe that this study should be conducted with the radiation modality that offers the best dosimetry achievable at our institution.
Conditions Studied
Interventions
- RADIATION Proton radiation
Study Locations (1)
California
- Loma Linda University Medical Center - Loma Linda
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2013-02-20 |
| Est. Completion | 2032-08 |
| Phase | NA |
What NCT01684904 shows while recruiting
NCT01684904 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 38 participants, a relatively small participant target, below the 485-participant average among 11 other Esophagus Cancer trials with a reported enrollment target (92% lower).
The record links to 1 condition, with Esophagus Cancer appearing as the primary indexed condition, and to 1 intervention - of which Proton radiation is the first listed.
NCT01684904 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT01684904 about?
NCT01684904 is a clinical study titled "Proton Therapy for Esophageal Cancer". The goal of this phase II study is to investigate the feasibility, toxicity and efficacy of a regimen incorporating a proven systemic regimen, carboplatin /paclitaxel, with conformal proton modality, followed by definitive surgery. In most combined-modality trials to date, chemotherapy regimens have...
What is the current status of trial NCT01684904?
This trial is currently recruiting. It is a NA study. The enrollment target is 38 participants. The study started on 2013-02-20. Estimated completion is 2032-08.
What conditions does trial NCT01684904 study?
This clinical trial studies the following conditions: Esophagus Cancer.
What interventions are being tested in trial NCT01684904?
The interventions under investigation include: Proton radiation (RADIATION).
Who is sponsoring clinical trial NCT01684904?
This trial is sponsored by Loma Linda University, which has 237 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01684904 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Esophagus Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01684904's enrollment target sits among peer trials
38 6th of 11 higher than 6 of 11 other Esophagus Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Esophagus Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Individualized Dose Escalation of 5-FU for Gastrointestinal Cancer
RECRUITING · NA
-
Proton Beam Therapy in the Treatment of Esophageal Cancer
ACTIVE NOT RECRUITING · NA
-
Ivonescimab in Comb. With FOLFOX in Advanced HER2 Neg. GEA
RECRUITING · Phase 2
-
Retrospective Review of Esophageal Cancer at MSKCC
RECRUITING
-
Mayo Clinic Upper Digestive Disease Survey
RECRUITING
-
CA-4948 in Combination With FOLFOX/PD-1 Inhibitor +/- Trastuzumab for Untreated Unresectable Gastric and Esophageal Cancer
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03310879 · 38 participants · Phase 2
Study of the CDK4/6 Inhibitor Abemaciclib in Solid Tumors Harboring Genetic Alterations in Genes Encoding D-Type Cyclins or Amplification of CDK4 or CDK6
- NCT03896269 · 38 participants · Phase 1
CPX-351 in Treating Patients With Relapsed or Refractory High Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
- NCT04085315 · 38 participants · Phase 1
Alisertib in Combination With Osimertinib in Metastatic EGFR-mutant Lung Cancer
- NCT04237623 · 38 participants · Phase 2
GM-CSF With Post-Transplant Cyclophosphamide
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI